News

Perth pharmaceutical manufacturing facility investment for sale – RWC Medical

By Nicolas Milner

RWC Medical’s Franz Stapelberg and Nicolas Milner have launched the sale campaign for an exceptional pharmaceutical manufacturing facility in the highly sought-after Balcatta industrial precinct,10km north of Perth’s CBD.

25 Delawney Street, Balcatta is being sold via an Expressions of Interest campaign, closing Thursday 24 April.

The 3,826sqm building on an 8,594sqm landholding is one of Australia’s few industrial sites to hold both Therapeutic Goods Administration (TGA) and Good Manufacturing Practice (GMP) certifications, making it a prized asset in the pharmaceutical sector.

The facility is underpinned by a secure 15-year Triple Net Lease commencing 1 June 2025, with options extending until 2060. The tenant, Evaris Pharma (formerly Perrigo Australia), is a well-established pharmaceutical company with a 40-year legacy, ensuring $1,511,270 per annum in net income with all outgoings covered.

“The NNN lease structure shifts responsibility for property taxes, insurance, maintenance, and capital expenditures to the tenant, ensuring minimal ownership costs for investors,” Franz Stapelberg said.

“This is not just another shed; properties like this rarely, if ever, come to the open market. Typically, assets of this calibre transact off-market among large private equity firms and public pharmaceutical companies.”

Nicolas Milner emphasised the unique positioning and accreditation of the asset.

“Evaris Pharma has positioned itself in an efficient, TGA- and GMP-accredited facility designed to accommodate its projected long-term growth. Close to $40 million has been invested into this facility to achieve both compliance accreditations and streamlined manufacturing,” he said.

With its rare pharmaceutical manufacturing approvals, large landholding, and long-term income certainty, this listing presents an exceptional opportunity for institutional investors and private equity firms seeking premium industrial assets.

Interest is expected to be strong given the scarcity of similar properties in the market.

Up to Date

Latest News